SLNO INVESTOR ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Fraud Investigation
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKAT XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman
Soleno Therapeutics: Why I'm Staying On The Sidelines [Seeking Alpha]
Soleno Therapeutics (NASDAQ:SLNO) was given a new $107.00 price target on by analysts at Robert W. Baird.
SLNO Investors: Contact Kirby McInerney LLP About Investigation into Soleno Therapeutics, Inc.